GPCR platform
Biortus provides comprehensive G protein-coupled receptor (GPCR) screening services for drug discovery, utilizing a wide range of biophysical and signaling assays to identify potential drug candidates. GPCRs, the largest receptor family for membrane proteins, account for over 30% of approved medications and are critical drug targets.
Our services include high-throughput screening and high-content analysis across more than 10 established GPCR targets. We offer a variety of assays, such as SPR, TSA, and TRIC, using different protein formats (detergent and nanodisc), as well as signaling assays like beta-arrestin accumulation and cAMP generation.Biortus is committed to supporting your drug discovery efforts through robust assay development and screening capabilities.
Surface expression
-
Bright field>FAM labeled GLP1R expression
-
Bright field>TRAMA labeled PAR2 expression
-
CETSA binding assay
-
cAMP assay
-
βarrestin recuitment assay
over 10+tested Targets, over 300+ready-to-use Targets
| GLP1R | GCGR | OX2R | DRD2 | HRH1 | GPR75 | A1AR |
| GIPR | OX1R | A2AR | HRH3 | M1R | β2AR | PAR2 |
Target specific platforms
